Eli Lilly is a large pharma headquartered in US. Over the past three years, Eli Lilly has been involved in 92 licensing and acquisition transactions, with a primary focus on Small Molecules (21 deals). The company currently has 50 active clinical trials, primarily in Neurology.
Deals (12mo)
62
Active Trials
50
Top Modality
Small Molecules
Focus Area
Neurology
Licensing, acquisition, and partnership transactions involving Eli Lilly in the past 12 months.
| Asset |
|---|
| Partner |
|---|
| Modality |
|---|
| Phase |
|---|
| Type |
|---|
| Date |
|---|
| vaccine candidates and platforms | LimmaTech Biologics | Vaccines | Unknown | acquisition | Jul 19, 2026 |
| in vivo CAR-T platform | Orna Therapeutics | CAR-T | Unknown | acquisition | Jul 18, 2026 |
| Ajax oncology platform | Eli Lilly and Company | Small Molecules | Unknown | acquisition | Jul 10, 2026 |
| Centessa Pharmaceuticals | Centessa Pharmaceuticals | Other | Unknown | acquisition | Jul 7, 2026 |
| AI-driven drug discovery multi-target collaboration | Insilico Medicine | Small Molecules | Discovery | collaboration | Jul 1, 2026 |
| multitarget oncology programs | Abbisko | Other | Discovery | collaboration | Jun 25, 2026 |
| cleminorexant | Centessa Pharmaceuticals | Small Molecules | Unknown | acquisition | Jun 23, 2026 |
| RNA exon-editing kidney disease program | Eli Lilly and Company | Oligonucleotides | Discovery | collaboration | Jun 15, 2026 |
| Ajax collaboration program | Ajax | Other | Unknown | collaboration | Jun 15, 2026 |
| Vaccine Co. portfolio | Eli Lilly and Company | Vaccines | Unknown | acquisition | Jun 15, 2026 |
Showing 10 of 20 recent transactions. Upgrade to Pro for full deal history with financials.
Therapeutic areas and modalities where Eli Lilly is most active based on deal history and clinical trial data.
Key indicators of Eli Lilly's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Acquisition Appetite
Strategic Priorities
Eli Lilly has 50 active clinical trials across 6 development phases.
3
Not Applicable
4
Phase 4
3
Unknown
16
Phase 1
19
Phase 2
5
Phase 3
Use Solidus to benchmark upfront payments, milestones, and royalties for Neurology assets — powered by data from 3,500+ real biopharma transactions.
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
Eli Lilly is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 92 deals over the past three years, Eli Lilly ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Eli Lilly include Neurology (21 deals and trials), Mega Deals (20 deals and trials), Metabolic (16 deals and trials), and Oncology (12 deals and trials). In terms of modality, Eli Lilly has shown particular interest in small molecules, gene therapy, vaccines.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Eli Lilly and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Eli Lilly's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.
© 2026 Ambrosia Ventures. All rights reserved.
Benchmarks powered by 1,600+ real biopharma licensing deals